Oncology
News from the FDA/CDC
Prostate cancer drug shortage leaves some with uncertainty
The therapy lutetium Lu 177 vipivotide tetraxetan will remain in limited supply until the drug’s manufacturer can ramp up production.
News
Melanoma screening: Consensus statement offers greater clarity
Overall, the panelists agreed that a risk-stratified approach is likely the most appropriate strategy for melanoma screening and follow-up and...
News
EPA seeks to limit ‘forever’ chemicals in U.S. drinking water
The Environmental Protection Agency is proposing a new rule that would greatly limit the concentration of endocrine-disrupting ‘forever’ chemicals...
Commentary
TikTok’s fave weight loss drugs: Link to thyroid cancer?
The TikTok videos may continue, the celebrity chatter may increase, and we, as physicians, will continue to look to real-world data with...
Commentary
Can particles in dairy and beef cause cancer and MS?
Researchers found single-stranded DNA rings that originated in viruses, which they named bovine meat and milk factors, in the intestines of...
Conference Coverage
Urine test predicts future bladder cancer 12 years before symptoms
The test, if validated in further studies, has the potential to serve as a cancer screening tool for individuals at elevated risk for bladder...
Conference Coverage
Atorvastatin cut anthracycline cardiac dysfunction in lymphoma
News
Skin reactions from melanoma targeted and immune therapies range from pruritus to SJS
Appearance of vitiligo is regarded as a good prognostic factor in the treatment of melanoma with various checkpoint inhibitors alone or in...
Commentary
The 5-year survival rate for pancreatic cancer is increasing
‘Research is making a difference. And we’re making progress against cancer in general,’ says expert.
News
More than 97K new cutaneous melanoma diagnoses expected in 2023
More than 1.3 million people in the United States live with cutaneous melanoma, and the overall 5-year survival is 93.7%.